Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RongCan (Shanghai) Biotech
Shanghai, Shanghai, Chinarongcanbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Rongcan Biotech is a Shanghai-based biopharmaceutical company specializing in the development of mRNA therapeutics and advanced lipid nanoparticle (LNP) delivery systems. Founded in 2020, the company has developed a proprietary LNP platform that enables precise, organ-specific delivery, including both hepatic and extra-hepatic targeting. Its research pipeline is primarily focused on infectious disease vaccines, cancer immunotherapies, and treatments for rare genetic disorders. By addressing the technical challenges of nucleic acid delivery, Rongcan Biotech aims to provide innovative solutions for significant unmet medical needs globally.
- Therapeutic areas
- OncologyRare DiseasesInfectious Diseases
- Modalities
- mRNA-based drugsLipid nanoparticle delivery therapy
- Industry
- Biotech
Beyond the preview
Go deeper on RongCan (Shanghai) Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RongCan (Shanghai) Biotech.